Thus, these findings argue against the routine use of continuous nebulization in the ED treatment of patients with acute asthma, and the decision to use one of these nebulization methods should be based on logistical and cost considerations. Overall, this Read More
Continuous vs Intermittent ^-Agonists in the Treatment of Acute Adult Asthma:
No benefit was observed after 1 h of treatment (severe asthma subgroup: SMD, -0.20; 95% CI, -0.43 to 0.04; x2, 3.5; df, 4; p = 0.5; moderate asthma subgroup: SMD, -0.04; 95% CI, -0.40 to 0.33; x2, 0.4; df, 1; Read More
Continuous vs Intermittent ^-Agonists in the Treatment of Acute Adult Asthma: Sensitivity Analyses
More specifically, there were no significant group differences in the SMD observed after 1 h of treatment (SMD, -0.15; 95% CI, -0.35 to 0.05) and after 2 to 3 h of treatment (SMD, -0.19; 95% CI, -0.39 to 0.01) [Fig Read More
Continuous vs Intermittent ^-Agonists in the Treatment of Acute Adult Asthma: Effects on Pulmonary Function
Results Sixty-two articles were identified in the initial search. Of these, reviewers found that 16 articles were potentially eligible. Most of the others were excluded because they were not clinical trials of patients with acute asthma. The reasons for subsequent Read More
Continuous vs Intermittent ^-Agonists in the Treatment of Acute Adult Asthma: Statistical Analysis
The two authors independently examined (title and abstract) the output generated from the search. Any potentially relevant articles were obtained, irrespective of the original language of publication. From the full text of potentially relevant articles, the reviewers assessed each study Read More
Continuous vs Intermittent ^-Agonists in the Treatment of Acute Adult Asthma: PEF
We searched for studies using the MEDLINE (1966 to 2001), EMBASE (1980 to 2001), and CINAHL (1982 to 2001) databases. The following MeSH terms were used in the search: Emerg* or acute or status and continuous or intermittent or multi-dose Read More
Continuous vs Intermittent ^-Agonists in the Treatment of Acute Adult Asthma
Inhaled (P2-agonists are the drugs of choice with which to treat patients with acute severe asthma. In comparison to the systemic approach, inhalation is associated with a more rapid onset of action and fewer systemic side effects. However, there are Read More
Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism: Asthmatic airways
The first possible shortcoming of this study was that the methacholine challenge was performed in only 45 of 88 patients, which would have resulted in a selection bias. The most important reason for not performing the methacholine challenge concerned the Read More
Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism: Discussion
In this study, the CTLA-4 promoter ( — 318 C/T) polymorphism was found to be associated with asthma severity, but not with asthma, atopy, or bronchial hyperresponsiveness. The CTLA-4 exon 1 (+ 49 A/G) polymorphism was shown to be associated Read More
Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism: Polymorphism
The distributions of genotypic frequencies were significantly different for the mild-to-moderate group and the severe group. In particular, the frequency of the T allele was 7.4% in the mild-to-moderate group and 20.4% in the severe group, and the association between Read More